Cenexi turnaround delay
Cenexi's break-even depends on achieving EUR 50 million quarterly revenue; any shortfall could delay profitability.
medium · analyst_questionGland Pharma Limited — Q2 FY26
Gland Pharma reported a strong Q2 FY26 with consolidated revenue of INR 14,869 million, up 6% YoY, and EBITDA of INR 3,139 million (21% margin).
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Milestone revenue volatility
Milestone revenue was lower in Q2 (INR 44-45 crore vs. normal INR 75-80 crore) due to timing and U.S. licensing slowdown, impacting quarterly comparisons.
low · management_commentaryROW business growth lumpiness
ROW revenue was flat due to a 53% decline in tech transfer/CMO revenue, though product sales grew 19%; recovery may take a few quarters.
low · management_commentary